SG11202009884YA - Growth differentiation factor 15 fusion proteins - Google Patents
Growth differentiation factor 15 fusion proteinsInfo
- Publication number
- SG11202009884YA SG11202009884YA SG11202009884YA SG11202009884YA SG11202009884YA SG 11202009884Y A SG11202009884Y A SG 11202009884YA SG 11202009884Y A SG11202009884Y A SG 11202009884YA SG 11202009884Y A SG11202009884Y A SG 11202009884YA SG 11202009884Y A SG11202009884Y A SG 11202009884YA
- Authority
- SG
- Singapore
- Prior art keywords
- fusion proteins
- differentiation factor
- growth differentiation
- growth
- factor
- Prior art date
Links
- 102000000597 Growth Differentiation Factor 15 Human genes 0.000 title 1
- 108010041834 Growth Differentiation Factor 15 Proteins 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862655108P | 2018-04-09 | 2018-04-09 | |
| PCT/US2019/026369 WO2019199685A1 (en) | 2018-04-09 | 2019-04-08 | Growth differentiation factor 15 fusion proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202009884YA true SG11202009884YA (en) | 2020-11-27 |
Family
ID=66251865
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202009884YA SG11202009884YA (en) | 2018-04-09 | 2019-04-08 | Growth differentiation factor 15 fusion proteins |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US12054527B2 (en) |
| EP (1) | EP3773656A1 (en) |
| JP (2) | JP7058670B2 (en) |
| KR (1) | KR20200140878A (en) |
| CN (1) | CN111954537A (en) |
| AR (1) | AR114476A1 (en) |
| AU (1) | AU2019253462A1 (en) |
| BR (1) | BR112020020823A2 (en) |
| CA (1) | CA3096097A1 (en) |
| CL (1) | CL2020002585A1 (en) |
| CO (1) | CO2020012563A2 (en) |
| CR (1) | CR20200510A (en) |
| EA (1) | EA202092419A1 (en) |
| IL (1) | IL277842A (en) |
| JO (1) | JOP20200258A1 (en) |
| MA (1) | MA52205A (en) |
| MX (1) | MX2020010659A (en) |
| PE (1) | PE20201350A1 (en) |
| PH (1) | PH12020551655A1 (en) |
| SG (1) | SG11202009884YA (en) |
| TW (1) | TW202003586A (en) |
| UY (1) | UY38177A (en) |
| WO (1) | WO2019199685A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170299608A1 (en) * | 2016-03-04 | 2017-10-19 | Ngm Biopharmaceuticals, Inc. | Compositions and methods for modulating body weight |
| SG11202009884YA (en) | 2018-04-09 | 2020-11-27 | Amgen Inc | Growth differentiation factor 15 fusion proteins |
| MX2021010737A (en) * | 2019-03-08 | 2021-09-28 | Amgen Inc | Growth differentiation factor 15 combination therapy. |
| JOP20210282A1 (en) * | 2019-04-23 | 2023-01-30 | Lg Chemical Ltd | Fusion polypeptide comprising fc region of immunoglobulin and gdf15 |
| CN113366024B (en) * | 2020-01-08 | 2024-11-05 | 上海翰森生物医药科技有限公司 | FGF21 mutant proteins and fusion proteins thereof |
| WO2022092915A1 (en) * | 2020-10-30 | 2022-05-05 | 가톨릭대학교 산학협력단 | Composition for preventing and treating immune diseases containing gdf15 as active ingredient |
| WO2023025120A1 (en) * | 2021-08-24 | 2023-03-02 | Sunshine Lake Pharma Co., Ltd. | Gdf15 fusion proteins and uses thereof |
| WO2023154953A1 (en) | 2022-02-14 | 2023-08-17 | Ngm Biopharmaceuticals, Inc. | Gdf15 polypeptides for treating and preventing autoimmune diseases |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| ZA811368B (en) | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| US4615885A (en) | 1983-11-01 | 1986-10-07 | Terumo Kabushiki Kaisha | Pharmaceutical composition containing urokinase |
| US5470582A (en) | 1992-02-07 | 1995-11-28 | Syntex (U.S.A.) Inc. | Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles |
| WO1999006445A1 (en) | 1997-07-31 | 1999-02-11 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-15 |
| ID30327A (en) | 1999-01-07 | 2001-11-22 | Lexigen Pharm Corp | EXPRESSION AND EXPORT OF ANTI OBESITY PROTEINS AS FUSION FOTIIN PROTEINS |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US20030103978A1 (en) | 2000-02-23 | 2003-06-05 | Amgen Inc. | Selective binding agents of osteoprotegerin binding protein |
| HU230603B1 (en) | 2000-12-07 | 2017-03-28 | Eli Lilly And Company | Glp-1 fusion proteins |
| JP4524074B2 (en) | 2001-03-09 | 2010-08-11 | アーナソン， バリー ジー． | Polymeric immunoglobulin fusion proteins targeting low affinity Fcγ receptors |
| JP4422949B2 (en) | 2001-06-26 | 2010-03-03 | 武田薬品工業株式会社 | TGF-β superfamily production / secretion promoter |
| US7332474B2 (en) | 2001-10-11 | 2008-02-19 | Amgen Inc. | Peptides and related compounds having thrombopoietic activity |
| US7101852B2 (en) | 2003-05-30 | 2006-09-05 | The Board Of Regents Of The University Of Texas System | Composition and method for treatment and prevention of restenosis |
| US20070148170A1 (en) | 2005-10-03 | 2007-06-28 | Desjarlais John R | Fc Variants With Optimized Fc Receptor Binding Properties |
| WO2005063815A2 (en) | 2003-11-12 | 2005-07-14 | Biogen Idec Ma Inc. | Fcϝ receptor-binding polypeptide variants and methods related thereto |
| CN1723220A (en) | 2003-11-13 | 2006-01-18 | 韩美药品工业株式会社 | A pharmaceutical composition comprising an immunoglobulin FC region as a carrier |
| EP1697520A2 (en) | 2003-12-22 | 2006-09-06 | Xencor, Inc. | Fc polypeptides with novel fc ligand binding sites |
| SI2441466T1 (en) | 2004-04-13 | 2015-01-30 | St Vincent's Hospital Sydney Limited Centre For Immunology | MIC-1 inhibiting agent |
| US20090042780A1 (en) | 2004-05-20 | 2009-02-12 | Acceleron Pharma Inc | Modified TGF-Beta Superfamily Polypeptides and Related Methods |
| US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
| CN1974601A (en) | 2005-11-28 | 2007-06-06 | 上海新生源医药研究有限公司 | New-type Fc fusion protein and its production process |
| EP2057191A1 (en) | 2006-08-18 | 2009-05-13 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling |
| CN101854947A (en) | 2007-08-16 | 2010-10-06 | 圣文森特医院悉尼有限公司 | Be used to regulate active medicament of macrophage inhibition factor (MIC-1) and method |
| PL2235064T3 (en) | 2008-01-07 | 2016-06-30 | Amgen Inc | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| WO2009141357A1 (en) | 2008-05-20 | 2009-11-26 | Roche Diagnostics Gmbh | Gdf-15 as biomarker in type 1 diabetes |
| WO2010017198A2 (en) | 2008-08-04 | 2010-02-11 | Five Prime Therapeutics, Inc. | Fgfr extracellular domain acidic region muteins |
| ES2434996T3 (en) | 2008-10-31 | 2013-12-18 | St Vincent's Hospital Sydney Limited | Prognosis methods in chronic kidney disease |
| WO2011063348A1 (en) | 2009-11-23 | 2011-05-26 | Amgen Inc. | Monomeric antibody fc |
| WO2011064758A2 (en) | 2009-11-30 | 2011-06-03 | Pfizer Limited | Fusion protein |
| US8372952B2 (en) | 2009-12-02 | 2013-02-12 | Amgen Inc. | Binding proteins that bind to human FGFR1C, human β-klotho and both human FGFR1C and human β-klotho |
| WO2011091078A2 (en) | 2010-01-19 | 2011-07-28 | Xencor, Inc. | Antibody fc variants with enhanced complement activity |
| ES2526981T3 (en) | 2010-07-12 | 2015-01-19 | Pfizer Limited | N-sulfonylbenzamides as voltage dependent sodium channel inhibitors |
| US8772343B2 (en) | 2010-07-12 | 2014-07-08 | Pfizer Limited | Chemical compounds |
| JP2013532185A (en) | 2010-07-12 | 2013-08-15 | ファイザー・リミテッド | Compound |
| CA2807213C (en) | 2010-08-26 | 2022-06-28 | F. Hoffman-La Roche Ag | Use of biomarkers in the assessment of the early transition from arterial hypertension to heart failure |
| EP2439535A1 (en) | 2010-10-07 | 2012-04-11 | F. Hoffmann-La Roche AG | Diagnosis of diabetes related heart disease and GDF-15 and Troponin as predictors for the development of type 2 diabetes mellitus |
| WO2012058768A1 (en) | 2010-11-05 | 2012-05-10 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the fc domain |
| US20140112926A1 (en) | 2011-03-16 | 2014-04-24 | Amgen Inc. | Fc VARIANTS |
| AU2012240102C1 (en) | 2011-04-08 | 2016-09-08 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (GDF-15) |
| EA201892619A1 (en) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | IMMUNOCONJUGATES CONTAINING INTERLEUKIN-2 MUTANT POLYPETIPS |
| EA201491413A1 (en) * | 2012-01-26 | 2015-03-31 | Эмджен Инк. | POLYPEPTIDE GROWTH FACTOR AND DIFFERENTIATION 15 (GDF-15) |
| US9550819B2 (en) * | 2012-03-27 | 2017-01-24 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
| SG10201913376XA (en) | 2012-04-20 | 2020-02-27 | Merus Nv | Methods and means for the production of ig-like molecules |
| JP6758832B2 (en) | 2012-12-21 | 2020-09-30 | アベオ ファーマシューティカルズ， インコーポレイテッド | Anti-GDF15 antibody |
| BR112015018104A2 (en) * | 2013-01-30 | 2017-11-21 | Ngm Biopharmaceuticals Inc | modified gdf15 polypeptides, their use, compositions comprising them and sterile container comprising said compositions |
| US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
| EA037355B1 (en) | 2013-07-31 | 2021-03-17 | Эмджен Инк. | Growth differentiation factor 15 (gdf-15) constructs |
| CN112851790A (en) | 2014-06-23 | 2021-05-28 | 诺华股份有限公司 | Site-specific protein modification |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| EP3157947A1 (en) | 2014-06-23 | 2017-04-26 | Novartis AG | Hsa-gdf-15 fusion polypeptide and use thereof |
| AU2015279525A1 (en) | 2014-06-24 | 2016-12-15 | Novo Nordisk A/S | MIC-1 fusion proteins and uses thereof |
| MY192917A (en) | 2014-07-30 | 2022-09-15 | Ngm Biopharmaceuticals Inc | Compositions and methods of use for treating metabolic disorders |
| CA2961587A1 (en) | 2014-10-31 | 2016-05-06 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
| CN108367053A (en) | 2015-12-22 | 2018-08-03 | 诺华股份有限公司 | The method that metabolic disease is treated or improved using growth and differentiation factor 15 (GDF-15) |
| US20170299608A1 (en) | 2016-03-04 | 2017-10-19 | Ngm Biopharmaceuticals, Inc. | Compositions and methods for modulating body weight |
| US10336812B2 (en) | 2016-05-10 | 2019-07-02 | Janssen Biotech, Inc. | GDF15 fusion proteins and uses thereof |
| TW201741333A (en) | 2016-05-24 | 2017-12-01 | 諾佛 儂迪克股份有限公司 | MIC-1 compounds and uses thereof |
| TWI724392B (en) | 2018-04-06 | 2021-04-11 | 美商美國禮來大藥廠 | Growth differentiation factor 15 agonist compounds and methods of using the same |
| SG11202009884YA (en) | 2018-04-09 | 2020-11-27 | Amgen Inc | Growth differentiation factor 15 fusion proteins |
| MX2021010737A (en) | 2019-03-08 | 2021-09-28 | Amgen Inc | Growth differentiation factor 15 combination therapy. |
-
2019
- 2019-04-08 SG SG11202009884YA patent/SG11202009884YA/en unknown
- 2019-04-08 JO JOP/2020/0258A patent/JOP20200258A1/en unknown
- 2019-04-08 KR KR1020207032157A patent/KR20200140878A/en not_active Application Discontinuation
- 2019-04-08 EA EA202092419A patent/EA202092419A1/en unknown
- 2019-04-08 WO PCT/US2019/026369 patent/WO2019199685A1/en active Application Filing
- 2019-04-08 CN CN201980024728.9A patent/CN111954537A/en active Pending
- 2019-04-08 JP JP2019562592A patent/JP7058670B2/en active Active
- 2019-04-08 BR BR112020020823-0A patent/BR112020020823A2/en unknown
- 2019-04-08 PE PE2020001560A patent/PE20201350A1/en unknown
- 2019-04-08 CA CA3096097A patent/CA3096097A1/en active Pending
- 2019-04-08 US US16/620,029 patent/US12054527B2/en active Active
- 2019-04-08 MX MX2020010659A patent/MX2020010659A/en unknown
- 2019-04-08 AU AU2019253462A patent/AU2019253462A1/en active Pending
- 2019-04-08 MA MA052205A patent/MA52205A/en unknown
- 2019-04-08 CR CR20200510A patent/CR20200510A/en unknown
- 2019-04-08 EP EP19719403.8A patent/EP3773656A1/en active Pending
- 2019-04-09 AR ARP190100931A patent/AR114476A1/en unknown
- 2019-04-09 UY UY0001038177A patent/UY38177A/en not_active Application Discontinuation
- 2019-04-09 TW TW108112268A patent/TW202003586A/en unknown
-
2020
- 2020-10-06 PH PH12020551655A patent/PH12020551655A1/en unknown
- 2020-10-07 CL CL2020002585A patent/CL2020002585A1/en unknown
- 2020-10-07 IL IL277842A patent/IL277842A/en unknown
- 2020-10-08 CO CONC2020/0012563A patent/CO2020012563A2/en unknown
-
2021
- 2021-01-14 US US17/148,761 patent/US11161889B2/en active Active
- 2021-10-05 US US17/494,001 patent/US20220017584A1/en not_active Abandoned
-
2022
- 2022-04-11 JP JP2022064965A patent/JP2022095856A/en not_active Withdrawn
-
2024
- 2024-06-18 US US18/746,427 patent/US20240327481A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| UY38177A (en) | 2019-07-31 |
| CL2020002585A1 (en) | 2020-12-04 |
| MA52205A (en) | 2021-02-17 |
| IL277842A (en) | 2020-11-30 |
| JP7058670B2 (en) | 2022-04-22 |
| WO2019199685A1 (en) | 2019-10-17 |
| CR20200510A (en) | 2020-11-26 |
| PE20201350A1 (en) | 2020-11-30 |
| EA202092419A1 (en) | 2021-02-05 |
| US11161889B2 (en) | 2021-11-02 |
| AR114476A1 (en) | 2020-09-09 |
| PH12020551655A1 (en) | 2021-07-26 |
| US20230143988A1 (en) | 2023-05-11 |
| US20210147500A1 (en) | 2021-05-20 |
| AU2019253462A1 (en) | 2020-11-26 |
| JP2020533271A (en) | 2020-11-19 |
| JOP20200258A1 (en) | 2020-10-11 |
| TW202003586A (en) | 2020-01-16 |
| BR112020020823A2 (en) | 2021-01-19 |
| US20220017584A1 (en) | 2022-01-20 |
| CA3096097A1 (en) | 2019-10-17 |
| US12054527B2 (en) | 2024-08-06 |
| US20240327481A1 (en) | 2024-10-03 |
| KR20200140878A (en) | 2020-12-16 |
| CO2020012563A2 (en) | 2020-10-30 |
| MX2020010659A (en) | 2020-10-28 |
| EP3773656A1 (en) | 2021-02-17 |
| CN111954537A (en) | 2020-11-17 |
| JP2022095856A (en) | 2022-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL277842A (en) | Growth differentiation factor 15 fusion proteins | |
| SG11202011743SA (en) | Fusion proteins comprising progranulin | |
| IL281954A (en) | Heterodimeric fc-fused proteins | |
| IL282267A (en) | Programmable dna base editing by nme2cas9-deaminase fusion proteins | |
| IL281962A (en) | Il-12 heterodimeric fc-fusion proteins | |
| EP3880814A4 (en) | Fusion protein | |
| EP3743438A4 (en) | Cytokine fusion proteins | |
| EP3620474A4 (en) | Human fibroblast growth factor 21 (hfgf21) fusion protein, preparation method therefor, and use thereof | |
| SG11202012004SA (en) | Rna-targeting fusion protein compositions and methods for use | |
| EP3757218A4 (en) | Fusion protein | |
| EP3755726A4 (en) | Fusion proteins for base editing | |
| ZA202005385B (en) | Growth differentiation factor 15 agonist compounds and methods of using the same | |
| IL290660A (en) | Therapeutic fusion proteins | |
| ZA202003845B (en) | Fusion proteins | |
| SG11202101904UA (en) | Spd-1 variant - fc fusion proteins | |
| IL273271A (en) | Fusion protein comprising an fgf-18 moiety | |
| ZA202007491B (en) | Stable fusion protein formulation | |
| EP3697428A4 (en) | Artificial secretion peptides for heterologous protein production | |
| IL281088A (en) | Flt3l-based chimeric proteins | |
| EP3848388A4 (en) | Fusion polypeptide comprising polypeptide region that can be o-glycosylated | |
| EP3873918A4 (en) | Insecticidal proteins | |
| GB201816873D0 (en) | Fusion protein | |
| IL290715A (en) | Nkg2d fusion proteins and uses thereof | |
| IL291618A (en) | Heterodimeric proteins | |
| EP3897104A4 (en) | Insecticidal proteins |